While GLP-1 agonist drugs are gaining attention for treating obesity, anorexia remains one of the deadliest mental illnesses, with no approved medications. Roger Cone, professor of molecular and integrative physiology, is investigating a critical neural circuit called the melanocortin system, which may hold the key to treating both conditions. In this Q&A, Cone explains the science behind targeting these neural pathways and how a University of Michigan startup aims to transform treatment options for eating disorders.
